Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707799 | 1.00 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6578863 | 1.00 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL10615023 | 0.98 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL10615017 | 0.98 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL15886548 | 0.95 | ALDH1A1 (0.38) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL8521036 | 0.95 | ALDH1A1 (0.38) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL13278810 | 0.91 | ALDH1A1 (0.36) | DPP4ALDH1A1GAACYP3A4POLB | |
| SCHEMBL8726681 | 0.87 | ALDH1A1 (0.33) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30713421 | 0.84 | ALDH1A1 (0.42) | DPP4ALDH1A1GAANOS2NOS3 | |
| SCHEMBL21696620 | 0.83 | DPP4 (0.35) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118267309-A | Essence composition containing chamomile extract and preparation method thereof | 广州中科医疗美容仪器有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-114560887-A | Preparation method of intermediate for preparing orlistat | 安徽美致诚药业有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-112174870-A | Preparation method and medicinal application of (R) -1-alkanoyl-2-substituted pyrrolidine-2-formamide | 蔡霈 | 2021-01-05 | — | — | CN | claimed |
| US-10329341-B2 | Collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-25 | — | — | US | claimed |
| US-20180030115-A1 | COLLAGEN MIMICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | claimed |
| US-9758569-B2 | Collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-09-12 | — | — | US | claimed |
| EP-3110795-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | Hikal Limited (IN) | 2017-01-04 | — | — | EP | claimed |
| WO-2015128718-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | HIKAL LIMITED (IN) | 2015-09-03 | — | — | WO | claimed |
| EP-1496891-B1 | METHODS FOR MODULATING PHOTOTOXICITY | UNIV ARIZONA STATE (US) | 2011-07-20 | — | — | EP | claimed |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2010-01-21 | — | — | US | claimed |
| WO-2007139914-A2 | COLLAGEN MIMICS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070275897-A1 | Collagen mimics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | claimed |
| US-6992071-B2 | Methods for modulating phototoxicity | BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2006-01-31 | — | — | US | claimed |
| EP-1496891-A2 | METHODS FOR MODULATING PHOTOTOXICITY | University Of Arizona (US) | 2005-01-19 | — | — | EP | claimed |
| US-20030223941-A1 | Methods for modulating phototoxicity | NIADYNE, INC. | 2003-12-04 | — | — | US | claimed |
| WO-2003088909-A2 | METHODS FOR MODULATING PHOTOTOXICITY | UNIVERSITY OF ARIZONA (US) | 2003-10-30 | — | — | WO | claimed |
| EP-0372484-B1 | Condensed benzene derivative | ZERIA PHARM CO LTD (JP) | 1994-10-26 | — | — | EP | claimed |
| EP-0010347-B1 | NOVEL SUBSTITUTED OMEGA-AROYL(PROPIONYL OR BUTYRYL)-L-PROLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1983-11-09 | — | — | EP | claimed |
| EP-0010347-A1 | Novel substituted omega-aroyl(propionyl or butyryl)-L-prolines, pharmaceutical compositions containing them and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-04-30 | — | — | EP | claimed |
| JP-63033361-A | — | — | None | — | — | JP | disclosed |
| CN-112469306-B | Composition, artificial nail composition, nail decorating material, artificial nail, storage container, image forming apparatus, and image forming method | 株式会社理光 | 2024-07-05 | — | — | CN | disclosed |
| CN-118267309-A | Essence composition containing chamomile extract and preparation method thereof | 广州中科医疗美容仪器有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118267309-A | Essence composition containing chamomile extract and preparation method thereof | 广州中科医疗美容仪器有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-114560887-B | Preparation method of orlistat intermediate | 安徽美致诚药业有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023217590-A1 | POLYAMIDE MICROCAPSULES | FIRMENICH SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023190156-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | 愛知製鋼株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230159622-A1 | COLLAGEN MIMICS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| US-11390662-B2 | Collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
| CN-114560887-A | Preparation method of intermediate for preparing orlistat | 安徽美致诚药业有限公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-2922535-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-110432469-A | A kind of drying production method and production line of shell class fruit | LUZHOU DENGSHI NATIVE PRODUCT CO LTD | 2019-11-12 | — | — | CN | disclosed |
| CN-110381926-A | Novel dosage forms | 德维科制药瑞士公司 | 2019-10-25 | — | — | CN | disclosed |
| US-10329341-B2 | Collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-25 | — | — | US | disclosed |
| CN-109280116-A | Constituent, solidfied material, image forming apparatus and image forming method | 株式会社理光 | 2019-01-29 | — | — | CN | disclosed |
| US-20180030115-A1 | COLLAGEN MIMICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | disclosed |
| US-9758569-B2 | Collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-09-12 | — | — | US | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| EP-1664050-B1 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NEUREN PHARMACEUTICALS LTD (NZ) | 2015-12-09 | — | — | EP | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| CN-102405211-B | Proline derivatives as cathepsin inhibitors | HOFFMANN LA ROCHE | 2015-01-21 | — | — | CN | disclosed |
| EP-2666774-B1 | Beta-lactamase Inhibitors | MERCK SHARP & DOHME (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014025658-A1 | PYRROLIDINE THROMBIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-8618152-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8552183-B2 | Process for the covalent coupling of two molecules by means of a diels-alder reaction with inverse electron requirement | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8519127-B2 | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy | NEUREN PHARMACEUTICALS LIMITED (AU) | 2013-08-27 | — | — | US | disclosed |
| CN-102958517-A | Formulations and delivery | LONDONPHARMA LTD | 2013-03-06 | — | — | CN | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1636208-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMA (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
| US-8067425-B2 | Neuroprotective bicyclic compounds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-11-29 | — | — | US | disclosed |
| EP-1496891-B1 | METHODS FOR MODULATING PHOTOTOXICITY | UNIV ARIZONA STATE (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2332935-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-03-03 | — | — | US | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009091856-A2 | BETA-LACTAMASE INHIBITORS | MERCK & CO., INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-22 | — | — | US | disclosed |
| WO-2007139914-A2 | COLLAGEN MIMICS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275897-A1 | Collagen mimics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | disclosed |
| US-7271192-B2 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2007-09-18 | — | — | US | disclosed |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-08-23 | — | — | US | disclosed |
| EP-1077218-B1 | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors | SIGMA TAU IND FARMACEUTI (IT) | 2007-05-16 | — | — | EP | disclosed |
| EP-1664050-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Neuren Pharmaceuticals Limited (NZ) | 2006-06-07 | — | — | EP | disclosed |
| EP-1636208-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005077969-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050090450-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS, INCORPORATED | 2005-04-28 | — | — | US | disclosed |
| WO-2005023815-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2005-03-17 | — | — | WO | disclosed |
| US-20050014815-A1 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004092162-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1090960-B1 | TWO-PACK TYPE CURABLE COMPOSITION AND HARDENER THEREFOR | KANEKA CORP (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6451972-B1 | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-09-17 | — | — | US | disclosed |
| US-6437094-B2 | FOR TREATING PATHOLOGIES RELATED TO ALTERED ALPHA V BETA 3 INTEGRIN-MEDIATED CELL ATTACHMENT, IN PARTICULAR WHEREIN INHIBITION OF ANGIOGENESIS IS DESIRED, FOR EXAMPLE IN TUMORS, ALSO ASSOCIATED WITH METASTASIS | SIGMA-TSU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-08-20 | — | — | US | disclosed |
| US-20020068695-A1 | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-06-06 | — | — | US | disclosed |
| US-6235877-B1 | ANGIOGENESIS INHIBITOR; ANTITUMOR AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-05-22 | — | — | US | disclosed |
| US-20010001309-A1 | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2001-05-17 | — | — | US | disclosed |
| EP-1090960-A1 | TWO-PACK TYPE CURABLE COMPOSITION AND HARDENER THEREFOR | Kaneka Corporation (JP) | 2001-04-11 | — | — | EP | disclosed |
| EP-1077218-A2 | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-02-21 | — | — | EP | disclosed |
| US-6168912-B1 | CONVERTING IN PARALLEL, A SET OF AT LEAST TWO DIFFERENT ALPHA-ALLYL CARBONYL MONOMERS OF DEFINED STRUCTURE, THEN OLIGOMERIZING THROUGH A HETEROATOM | MARTEK BIOSCIENCES CORPORATION | 2001-01-02 | — | — | US | disclosed |
| US-5783709-A | Stereoselective process for making substituted amino acid derivatives | MERCK & CO., INC. (US) | 1998-07-21 | — | — | US | disclosed |
| US-5783709-A | Stereoselective process for making substituted amino acid derivatives | MERCK & CO., INC. (US) | 1998-07-21 | — | — | US | disclosed |
| EP-0372484-B1 | Condensed benzene derivative | ZERIA PHARM CO LTD (JP) | 1994-10-26 | — | — | EP | disclosed |
| CN-1072337-A | SKIN CARE CREAM | DAILY CHEMICAL PLANT SUZHOU RU (CN) | 1993-05-26 | — | — | CN | disclosed |
| US-5028604-A | Cognition Activators | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-02 | — | — | US | disclosed |
| US-4992541-A | Antiinflammatory, antidegenerative agents | MERCK & CO., INC. (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0411929-A1 | A process for the preparation of 1,1-dioxo-7-substituted cephems | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | disclosed |
| EP-0372484-A2 | Condensed benzene derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1990-06-13 | — | — | EP | disclosed |
| JP-S6333361-A | DIPEPTIDE DERIVATIVE, ITS PRODUCTION AND USE THEREOF | SUNTORY LTD | 1988-02-13 | — | — | JP | disclosed |
| US-4668397-A | CYCLODIMERIZATION, TETRAPEPTIDES | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1987-05-26 | — | — | US | disclosed |
| US-4325943-A | HYPOTENSIVE AGENTS, DIURETICS | E. R. SQUIBB & SONS, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4325945-A | Mixed disulfides | E. R. SQUIBB & SONS, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4325944-A | HYPOTENSIVE AGENTS, DIURETICS | E. R. SQUIBB & SONS, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4284624-A | HYPOTENSIVE PEPTIDES | E. R. SQUIBB & SONS, INC. (US) | 1981-08-18 | — | — | US | disclosed |
| US-4284624-A | HYPOTENSIVE PEPTIDES | E. R. SQUIBB & SONS, INC. (US) | 1981-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | PMP22, IAPP, GCG | DPP4 996/4885DPP8 1659/4885DPP9 1891/4885 |
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | PRSS1, SERPINB1, SPINT2 | DPP4 14/4885DPP8 58/4885DPP9 68/4885 |
| US-20050090450-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | DPP4 14/4885DPP8 55/4885DPP9 66/4885 |
| US-20050014815-A1 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | IDO1, IDO2, TPH2 | DPP4 1407/4885DPP8 2738/4885DPP9 2391/4885 |
| US-20150315141-A1 | Thrombin Inhibitors | F3, F2, F9 | DPP4 2254/4885DPP8 815/4885DPP9 644/4885 |
| US-20010001309-A1 | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors | VCAM1, ITGB1, ITGB3 | DPP4 2959/4885DPP8 3313/4885DPP9 1745/4885 |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | CX3CR1, NR3C2, NR4A2 | DPP4 3002/4885DPP8 4177/4885DPP9 4854/4885 |
| US-20020068695-A1 | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors | VCAM1, ITGB1, ITGB3 | DPP4 2959/4885DPP8 3313/4885DPP9 1745/4885 |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | DPP4 413/4885DPP8 791/4885DPP9 756/4885 |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NLN, GAP43, BAD | DPP4 2301/4885DPP8 2587/4885DPP9 4370/4885 |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | DPP4 13/4885DPP8 53/4885DPP9 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.